Appendix J: Sample Obstetric Outpatient Intravenous Iron Infusion Order Set

Note: This is a SAMPLE developed for a particular facility as an example to work from. You may need to adjust based on the individual circumstances of your facility.

*May be modified for an inpatient order set		
Facility Name:		
Patient Name:	DOB:	Date:
Physician Name:		
Physician Call Back Number for Emergencies:		
Diagnosis (check):		
☐ Iron deficiency anemia in pregnancy: GA 1	4 - 27.6 weeks (ICD10: 099	.012, D50.9)
☐ Iron deficiency anemia in pregnancy: GA ≥	28 weeks (ICD10: 099.013	, D50.9)
☐ Postpartum anemia (outpatient) (ICD10: 0	90.81)	
☐ Other:		
Hgb/Hct:Ferritin Level: Phospha	ite (if to receive ferric carbo	oxymaltose)
Iron Order: (Note: Populate with your institution depending on payor mix; choices may consider pan example of an iron sucrose dosing calculation than simply using a typical 1-gram dose which m	patient convenience and/on if desiring to calculate an	r compliance. See below for individualized dose rather
☐ Low Molecular Weight Iron Dextran (LMW first 25 mg (mL) IV over 15 minutes. If robservation, infuse the rest of bag content hours)	no reaction following a few	minutes to 15-minute
☐ Iron Sucrose (Venofer): 500 mg in 250 mL Day (within 1-7 days of Day 1 dose)	•	urs x 2 doses on Day 1 and
☐ Iron Sucrose (Venofer): 200 mg in 100 mL and Days (doses within 1-7 days		0 minutes x 5 doses on Day 1
☐ Ferric Carboxymaltose (Injectafer) (Patient than 2 mg/mL), Infuse over 15-30 minutes	<u>. </u>	•
☐ Ferric Carboxymaltose (Injectafer) (Patient (must not be less than 2 mg/mL), Infuse or		

Pre-medications: NO medications are needed in most patients

- Administer MethylPREDNISolone 125 mg (SOLU-Medrol) IV x1 prior to iron infusion IF:
- Patient is on any medication for asthma OR
- Patient has 2+ allergies OR
- Allergies defined by unexpected reactions (e.g., rash, swelling, anaphylaxis, itching). Does NOT include expected side effects to medications.

Treatment of Mild/Moderate Infusion Reactions: defined as any of the following:

- Fishbane reactions: myalgias (e.g., backpain/back tightness), flushing, dyspnea, arthralgias OR
- Non-allergic complement activated pseudoallergy reactions: urticaria, pruritis, rash, nausea, headache, mild hypotension/hypertension
- Stop the infusion. Lay patient on side. Monitor for 15 minutes for symptom resolution
- If symptoms resolve after 15 minutes:
- Resume the infusion at half the rate. If patient tolerates the infusion for the first 15 minutes, may increase the rate slowly to original rate.
- If symptoms DO NOT resolve after 15 minutes:
- Administer MethylPREDNISolone (SOLU-Medrol) 125mg IV PRN x1 and notify the physician. Do not resume the infusion.
- If symptoms do not resolve after MethylPREDNISolone administration, contact the physician for symptom-specific treatment (e.g., antihistamine for itching)

Treatment of Severe Infusion Reactions: defined as any of the following:

- ▶ Persistent significant hypotension (SBP drop of 30 mmHg from baseline or SBP < 90 mmHg) OR
- Angioedema of tongue or airway <u>OR</u>
- > Symptom involvement of 2+ organ systems that are cardiovascular, respiratory, gastrointestinal, or skin in origin (e.g., chest pain with bronchospasm)
- Stop the infusion and administer rescue medications:
- MethylPREDNISolone (SOLU-Medrol) 125mg IVPRN x1 AND
- EPINEPHrine 0.3 IM PRN x1 AND
- NS bolus 1000 mL IV PRN x1

	Notify the	physician,	activate (Code Blu	e and	transfer to	the	emergen	cy room
--	------------	------------	------------	----------	-------	-------------	-----	---------	---------

Baseline vitals and per unit standard

Observe patient for at least 30 minutes following completion

Physician Signature:

Date:

Ganzoni Formula:

Calculate total Fe dose need:

Fe need = wt. (kg) x 0.24 x (target Hgb – current Hgb in gm/L) + 500 mg

Example: 70 kg (pre-pregnancy weight) woman with Hgb of 7.0 gm/L and a target of 11.0 gm/L

= 70 kg x 0.24 x (target: 110 gm/L — actual: 70 gm/L) + 500 mg

Remember: 7 gm/dL = 70 gm/L

Remember: Use pre-pregnancy weight (kg)

= 672 mg + 500 mg = 1172 mg (This is usually rounded to 100 or 200 mg increments)

Ganzoni A. M. Intravenous iron-dextran: therapeutic and experimental possibilities. *Schweizerische Medizinische Wochenschrift*. 1970;100(7):301–303.

Courtesy of Long Beach Miller Children's/Miller Children's and Women's Hospital 2021 (Used with permission of Miller Children's and Women's Hospital)